| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/19/2009 | WO2009021931A1 Vaccines |
| 02/19/2009 | WO2009021468A1 Cell-penetrating peptides and use thereof bonded to biomolecules having therapeutic action |
| 02/19/2009 | WO2009021291A1 Mycobacterium vaccine formulation |
| 02/19/2009 | WO2009006141A3 Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof |
| 02/19/2009 | WO2009002380A3 Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
| 02/19/2009 | WO2008157356A3 Antibody formulations |
| 02/19/2009 | WO2008156629A3 Methods and agents for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells |
| 02/19/2009 | WO2008151637A3 Neuroplastin derived peptides |
| 02/19/2009 | WO2008150530A3 Cripto binding molecules |
| 02/19/2009 | WO2008148057A3 Cationic lipids compositions and methods for enhancing immune responses to vaccines |
| 02/19/2009 | WO2008146165A3 Kit of parts for the treatment of cancer or infectious diseases |
| 02/19/2009 | WO2008145401A3 Mutated parvovirus structural proteins as vaccines |
| 02/19/2009 | WO2008133706A3 Fully human anti-vegf antibodies and methods of using |
| 02/19/2009 | WO2008073615A4 N-glycosylation mutant of melanoma differentiation associated gene-7 |
| 02/19/2009 | WO2007104511A8 Cancer vaccine |
| 02/19/2009 | WO2006029173A3 Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12 |
| 02/19/2009 | US20090049561 Non-human animal exhibiting bone metastasis of tumor cells |
| 02/19/2009 | US20090048122 Stabilized polypeptide compositions |
| 02/19/2009 | US20090047660 Antibodies for oncogenic strains of HPV and methods of their use |
| 02/19/2009 | US20090047353 Changing th1/th2 balance in split influenza vaccines with adjuvants |
| 02/19/2009 | US20090047348 Poly(organophosphazene) hydrogels for drug delivery, preparation method thereof and use thereof |
| 02/19/2009 | US20090047339 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 02/19/2009 | US20090047307 Chemo-Immunotherapy Method |
| 02/19/2009 | US20090047306 Adjuvant compositions |
| 02/19/2009 | US20090047303 Method for improving the immunogenicity of plasmodium antigens |
| 02/19/2009 | US20090047302 Chimaeric Human Papillomavirus 16 L1 Virus Like Particles and a Method for Preparing the Particles |
| 02/19/2009 | US20090047301 Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies |
| 02/19/2009 | US20090047300 Blood-brain barrier epitopes and uses thereof |
| 02/19/2009 | US20090047299 Modified alpha-galactosyl ceramides for staining and stimulating natural killer t cells |
| 02/19/2009 | US20090047298 Immune system stimulant and process of manufacturing the same |
| 02/19/2009 | US20090047297 Microfluid system for the isolation of bilogical particles using immunomagnetic separation |
| 02/19/2009 | US20090047296 Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases |
| 02/19/2009 | US20090047295 Methods and Compositions for Reducing Stemness in Oncogenesis |
| 02/19/2009 | US20090047294 Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
| 02/19/2009 | US20090047293 immunization; comprised of a fusion protein; bioterrorism; plague |
| 02/19/2009 | US20090047292 Graft rejection suppressors |
| 02/19/2009 | US20090047291 Modulators of hepatocyte growth factor activator |
| 02/19/2009 | US20090047290 Monoclonal antibodies against beta3 integrins |
| 02/19/2009 | US20090047289 Osteopontin Specific Antibodies and Methods of Use Thereof |
| 02/19/2009 | US20090047288 Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity |
| 02/19/2009 | US20090047287 Modulation of bone formation |
| 02/19/2009 | US20090047286 H2n3 influenza a viruses and methods of use |
| 02/19/2009 | US20090047285 Compositions and methods for diagnosing and treating cancer |
| 02/19/2009 | US20090047284 Methods and compositions for PDGF-C activation and inhibition |
| 02/19/2009 | US20090047283 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/19/2009 | US20090047282 Prophylactic/Therapeutic Agent for Cancer |
| 02/19/2009 | US20090047281 Activin-ActRII antagonists and uses for increasing red blood cell levels |
| 02/19/2009 | US20090047280 Antibody inhibiting infection of papillomavirus |
| 02/19/2009 | US20090047279 (R)-N-Stereoisomers of 7,8-Saturated-4,5-Epoxy-Morphinanium Analogs |
| 02/19/2009 | US20090047278 Novel Combinational Use of Sulfonamide Compound |
| 02/19/2009 | US20090047277 Recombinant il-9 antibodies and uses thereof |
| 02/19/2009 | US20090047276 Methods for increasing cell or tissue regeneration in a vertebrate subject |
| 02/19/2009 | US20090047275 Modulating calvarial osteoblast differentiation; fracture repair |
| 02/19/2009 | US20090047274 Diagnostic and therapeutic target cdc2l6 proteins for neurodegenerative diseases |
| 02/19/2009 | US20090047247 Pyrrolidine Derivatives |
| 02/19/2009 | US20090047246 Novel inhibitors of hepatitis c virus replication |
| 02/19/2009 | US20090047217 Polynucleotides Encoding Members of the Human B Lymphocyte Activation Antigen B7 Family and Polypeptides Encoded Thereby |
| 02/19/2009 | US20090047213 Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| 02/19/2009 | US20090047212 Urothelial differentiation of urothelial carcinoma: a bladder cancer stem cell model |
| 02/19/2009 | US20090047211 Anti-mesothelin antibodies useful for immunological assays |
| 02/19/2009 | US20090047210 Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1 |
| 02/19/2009 | CA2722304A1 Immunoglobulins directed to bacterial, viral and endogeneous polypeptides |
| 02/19/2009 | CA2697265A1 Method of treating autoimmune disease with mesenchymal stem cells |
| 02/19/2009 | CA2696630A1 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 02/19/2009 | CA2696563A1 Peptides for vaccine |
| 02/19/2009 | CA2696360A1 Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
| 02/19/2009 | CA2696068A1 Compositions and methods for the treatment and prophylaxis of hypertension |
| 02/19/2009 | CA2696047A1 A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| 02/19/2009 | CA2695997A1 High affinity human antibodies to human nerve growth factor |
| 02/19/2009 | CA2695969A1 Regulators of mmp-9 and uses therof |
| 02/19/2009 | CA2695477A1 Vaccines |
| 02/19/2009 | CA2694973A1 Toll like receptor modulators |
| 02/19/2009 | CA2694735A1 Cell-penetrating peptides and use thereof bonded to biomolecules with therapeutic action |
| 02/19/2009 | CA2691819A1 Binding peptides having a c-terminally disposed specific binding domain |
| 02/19/2009 | CA2686817A1 Methods for the directed expansion of epitopes for use as antibody ligands |
| 02/19/2009 | CA2683748A1 Mutants of cholesterol-dependent cytolysins and uses thereof |
| 02/18/2009 | EP2025754A2 Moraxella (Branhamella) catarrhalis antigens |
| 02/18/2009 | EP2025749A1 Humanized anti-human osteopontin antibody |
| 02/18/2009 | EP2025746A1 Dendritic cells |
| 02/18/2009 | EP2025686A2 Alpha anticholine kinase monoclonal antibodies and their use in analytical techniques for the diagnosis of cancer and the preparation of medicinal products |
| 02/18/2009 | EP2025682A2 Human endokine alpha |
| 02/18/2009 | EP2025346A1 Muscle regeneration promoter |
| 02/18/2009 | EP2025345A1 KIM-1 antagonists and use to modulate immune system |
| 02/18/2009 | EP2024748A2 Monoclonal anti-annexin a3 antibodies for the detection of prostate carcinoma |
| 02/18/2009 | EP2024538A2 Compositions for and methods of identifying antigens |
| 02/18/2009 | EP2024497A2 Liga and ligb proteins (leptospiral ig-like (lig) domains) for vaccination and diagnosis |
| 02/18/2009 | EP2024395A2 Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
| 02/18/2009 | EP2024394A2 Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof |
| 02/18/2009 | EP2024393A2 Neutralizing antibodies to influenza viruses |
| 02/18/2009 | EP2024392A2 Stabilized polypeptide compositions |
| 02/18/2009 | EP2023955A2 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
| 02/18/2009 | EP2023954A2 Immunological composition |
| 02/18/2009 | EP2023952A2 Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| 02/18/2009 | EP2023946A1 Inhibition of gliotoxin |
| 02/18/2009 | EP2023897A1 Preparation of antibody or an antibody fragment-targeted immunoliposomes for systemic administration of therapeutic or diagnostic agents and uses thereof |
| 02/18/2009 | EP1576368B1 Methods and compositions for enhancing fibrocyte formation |
| 02/18/2009 | EP1569958B1 Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
| 02/18/2009 | EP1533320B1 HUMAN IgM ANTIBODY INDUCING APOPTOSIS IN HIV-INFECTED CELLS AND REMEDY FOR HIV-INFECTION |
| 02/18/2009 | EP1140157B1 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| 02/18/2009 | EP1135467B1 Psca: prostate stem cell antigen and uses thereof |